Literature DB >> 8699064

Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A.

S Bavari1, B Dyas, R G Ulrich.   

Abstract

Superantigens exert their pathologic effects by direct binding to major histocompatibility complex (MHC) class II molecules and T cell antigen receptors (TCR), thus circumventing the normal, antigen-specific immune response. A direct link between disease and toxin suggests an excellent opportunity for vaccine intervention. Site-directed mutants of staphylococcal enterotoxin A (SEA) that have attenuated binding to either the TCR or the MHC class II molecule were developed. Both kinds of SEA mutants induced high levels of antibody against SEA when used as vaccines, and the immunized animals were fully protected when challenged with wild type toxin. However, a residual lethality was associated with the attenuated TCR-binding mutant. These results, combined with an understanding of the molecular nature of superantigen and receptor interactions, indicate that targeting MHC class II binding by site-directed mutagenesis will produce the most effective vaccine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699064     DOI: 10.1093/infdis/174.2.338

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Structural basis for abrogated binding between staphylococcal enterotoxin A superantigen vaccine and MHC-IIalpha.

Authors:  Heike I Krupka; Brent W Segelke; Robert G Ulrich; Sabine Ringhofer; Mark Knapp; Bernhard Rupp
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection.

Authors:  Dong-Liang Hu; Jing-Chun Cui; Katsuhiko Omoe; Hiroshi Sashinami; Yuichi Yokomizo; Kunihiro Shinagawa; Akio Nakane
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Adaptive Immunity Against Staphylococcus aureus.

Authors:  Hatice Karauzum; Sandip K Datta
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

4.  Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality.

Authors:  R D LeClaire; S Bavari
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Immunopathophysiological aspects of an emerging neonatal infectious disease induced by a bacterial superantigen.

Authors:  N Takahashi; H Kato; K Imanishi; K Miwa; S Yamanami; H Nishida; T Uchiyama
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

6.  Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock.

Authors:  Avanish K Varshney; Xiaobo Wang; Emily Cook; Kaushik Dutta; Matthew D Scharff; Michael J Goger; Bettina C Fries
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

7.  Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model.

Authors:  B G Stiles; A R Garza; R G Ulrich; J W Boles
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B.

Authors:  Chad J Roy; Kelly L Warfield; Brent C Welcher; Raoul F Gonzales; Tom Larsen; Julie Hanson; Chella S David; Theresa Krakauer; Sina Bavari
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

9.  Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination.

Authors:  Ross D LeClaire; Robert E Hunt; Sina Bavari
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

10.  Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock.

Authors:  L Vincent Collins; Kristina Eriksson; Robert G Ulrich; Andrej Tarkowski
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.